Loading
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Previous close
$23.30
−$0.64 · -2.67%
Pre-market
$23.00
−$0.30 · -1.29%
Sep 14, 7:00 AM ET
Regular session · ET · Market data may be delayed.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Day range
Current $23.30
52-week range
Current $23.30
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
57
Fair Value
Sentiment
57
Mixed
Risk
47
Elevated Risk
Momentum
85
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Day range
Current $23.30
52-week range
Current $23.30
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 6.5M USD | 1.49M USD | — | — |
| Gross profit | 6.5M USD | 1.49M USD | — | — |
| Research and development | 67.45M USD | 40.95M USD | 25.92M USD | 14.3M USD |
| Selling, general, and administrative | 12.6M USD | 11.31M USD | 7.68M USD | 5.11M USD |
| Operating expenses | 81.18M USD | 53.54M USD | 34.79M USD | 19.76M USD |
| Interest income | 11.01M USD | 8.1M USD | 5.38M USD | 1.65M USD |
| Depreciation and amortization | 2.33M USD | 1.58M USD | 1.2M USD | 445K USD |
| Operating income | −74.68M USD | −52.05M USD | −34.79M USD | −19.76M USD |
| Net income | −63.73M USD | −43.98M USD | −28.64M USD | −17.93M USD |
Company facts updated Sep 14, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$37.40
60.52% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM12.95M0.02%78.38B USD0.19%$288.89+0.41%
Vanguard Morningstar Total Stock Market ETFVTI12.91M0.00%2.3T USD0.03%$376.31+0.82%
Vanguard Extended Market ETFVXF4.73M0.00%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Growth ETFIWO3.28M0.02%14.39B USD0.24%$367.63+0.54%
Vanguard Russell 2000 ETFVTWO2.63M0.01%17.4B USD0.06%$116.76+0.36%
Schwab U.S. Small-Cap ETFSCHA2.11M0.01%22.43B USD0.03%$33.79+0.42%
God Bless America ETFYALL1.58M1.81%87.12M USD0.65%$43.65+0.67%
iShares Russell 2000 Value ETFIWN1.43M0.01%14.34B USD0.24%$219.69+0.33%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAGod Bless America ETFYALLiShares Russell 2000 Value ETFIWNAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
